CompletedPhase 2

A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

United Kingdom158 participantsStarted 2022-03-23

Plain-language summary

A Phase 2 double-blind, multi-site, placebo-controlled, parallel-group design to assess the efficacy, safety and dose-response characterisation of STS-01 for the treatment of mild- moderate alopecia areata.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Active alopecia areata (less than 50% SALT score, present for at least 6 months)
✓. Not currently receiving treatment for hair loss
✓. Eighteen years of age or more
✓. Affected skin with normal appearance and no grossly evident epidermal alteration such as scaling or follicular abnormalities

What they're measuring

Relative change from baseline in Alopecia areata severity measured using the Severity of Alopecia Tool (SALT) at 6 months

Timeframe: 6 Months

Trial details

NCT IDNCT06402630

SponsorSoterios Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-04-01

View on ClinicalTrials.gov More Alopecia Areata trials